Ganesh Raj
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Figure S1. ZNF397-deficiency has bifurcated effects on PCa with or without AR inhibition. Figure S2. The impact of ZNF397-deficiency on AR protein and AR cistrome. Figure S3. ZNF397 is required for the activation of canonical AR transcriptional program. Figure S4. ZNF397-KO impairs DHT-induced AR signaling activation. Figure S5. ZNF397-KO promotes multilineage and lineage plastic gene expression. Figure S6. ZNF397-KO promotes stem-like and EMT-like transcriptional programs. Figure S7. ZNF397-KO led to induction of TET2 downstream genes. Figure S8. ZNF397-KO promotes transcriptional activation of TET2 downstream genes. Figure S9. ZNF397-deficiency has bifurcated effects on AR-dependent vs AR-independent PCas. Figure S10. Targeting TET2-driven epigenetic rewiring to overcome resistance.
Year:
2024
Cancer cells exhibit phenotypical plasticity and epigenetic reprogramming that allows them to evade lineage-dependent targeted treatments by adopting lineage plasticity. The underlying mechanisms by which cancer cells exploit the epigenetic regulatory machinery to acquire lineage plasticity and therapy resistance remain poorly understood. We identified zinc finger protein 397 (ZNF397) as a bona fide coactivator of the androgen receptor (AR), essential for the transcriptional program governing AR-driven luminal lineage. ZNF397 deficiency facilitates the transition of cancer cell from an AR-driven luminal lineage to a ten-eleven translocation 2 (TET2)-driven lineage plastic state, ultimately promoting resistance to therapies inhibiting AR signaling. Intriguingly, our findings indicate that a TET2 inhibitor can eliminate the resistance to AR-targeted therapies in ZNF397-deficient tumors. These insights uncover a novel mechanism through which prostate cancer acquires lineage plasticity via epigenetic rewiring and offer promising implications for clinical interventions designed to overcome therapy resistance dictated by lineage plasticity. Significance: This study reveals a bifurcated role of ZNF397, and a TET2–driven epigenetic mechanism regulating tumor lineage plasticity and therapy response in prostate cancer, enhances the understanding of drug resistance, and unveils a new therapeutic strategy for overcoming androgen receptor-targeted therapy resistance.
Year:
2024
Figure S1. ZNF397-deficiency has bifurcated effects on PCa with or without AR inhibition. Figure S2. The impact of ZNF397-deficiency on AR protein and AR cistrome. Figure S3. ZNF397 is required for the activation of canonical AR transcriptional program. Figure S4. ZNF397-KO impairs DHT-induced AR signaling activation. Figure S5. ZNF397-KO promotes multilineage and lineage plastic gene expression. Figure S6. ZNF397-KO promotes stem-like and EMT-like transcriptional programs. Figure S7. ZNF397-KO led to induction of TET2 downstream genes. Figure S8. ZNF397-KO promotes transcriptional activation of TET2 downstream genes. Figure S9. ZNF397-deficiency has bifurcated effects on AR-dependent vs AR-independent PCas. Figure S10. Targeting TET2-driven epigenetic rewiring to overcome resistance.
Year:
2024
Cancer cells exhibit phenotypical plasticity and epigenetic reprogramming that allows them to evade lineage-dependent targeted treatments by adopting lineage plasticity. The underlying mechanisms by which cancer cells exploit the epigenetic regulatory machinery to acquire lineage plasticity and therapy resistance remain poorly understood. We identified zinc finger protein 397 (ZNF397) as a bona fide coactivator of the androgen receptor (AR), essential for the transcriptional program governing AR-driven luminal lineage. ZNF397 deficiency facilitates the transition of cancer cell from an AR-driven luminal lineage to a ten-eleven translocation 2 (TET2)-driven lineage plastic state, ultimately promoting resistance to therapies inhibiting AR signaling. Intriguingly, our findings indicate that a TET2 inhibitor can eliminate the resistance to AR-targeted therapies in ZNF397-deficient tumors. These insights uncover a novel mechanism through which prostate cancer acquires lineage plasticity via epigenetic rewiring and offer promising implications for clinical interventions designed to overcome therapy resistance dictated by lineage plasticity. Significance: This study reveals a bifurcated role of ZNF397, and a TET2–driven epigenetic mechanism regulating tumor lineage plasticity and therapy response in prostate cancer, enhances the understanding of drug resistance, and unveils a new therapeutic strategy for overcoming androgen receptor-targeted therapy resistance.
Year:
2024
Figure S1. ZNF397-deficiency has bifurcated effects on PCa with or without AR inhibition. Figure S2. The impact of ZNF397-deficiency on AR protein and AR cistrome. Figure S3. ZNF397 is required for the activation of canonical AR transcriptional program. Figure S4. ZNF397-KO impairs DHT-induced AR signaling activation. Figure S5. ZNF397-KO promotes multilineage and lineage plastic gene expression. Figure S6. ZNF397-KO promotes stem-like and EMT-like transcriptional programs. Figure S7. ZNF397-KO led to induction of TET2 downstream genes. Figure S8. ZNF397-KO promotes transcriptional activation of TET2 downstream genes. Figure S9. ZNF397-deficiency has bifurcated effects on AR-dependent vs AR-independent PCas. Figure S10. Targeting TET2-driven epigenetic rewiring to overcome resistance.
Year:
2024
Cancer cells exhibit phenotypical plasticity and epigenetic reprogramming that allows them to evade lineage-dependent targeted treatments by adopting lineage plasticity. The underlying mechanisms by which cancer cells exploit the epigenetic regulatory machinery to acquire lineage plasticity and therapy resistance remain poorly understood. We identified zinc finger protein 397 (ZNF397) as a bona fide coactivator of the androgen receptor (AR), essential for the transcriptional program governing AR-driven luminal lineage. ZNF397 deficiency facilitates the transition of cancer cell from an AR-driven luminal lineage to a ten-eleven translocation 2 (TET2)-driven lineage plastic state, ultimately promoting resistance to therapies inhibiting AR signaling. Intriguingly, our findings indicate that a TET2 inhibitor can eliminate the resistance to AR-targeted therapies in ZNF397-deficient tumors. These insights uncover a novel mechanism through which prostate cancer acquires lineage plasticity via epigenetic rewiring and offer promising implications for clinical interventions designed to overcome therapy resistance dictated by lineage plasticity. Significance: This study reveals a bifurcated role of ZNF397, and a TET2–driven epigenetic mechanism regulating tumor lineage plasticity and therapy response in prostate cancer, enhances the understanding of drug resistance, and unveils a new therapeutic strategy for overcoming androgen receptor-targeted therapy resistance.
Year:
2024
Figure S1. ZNF397-deficiency has bifurcated effects on PCa with or without AR inhibition. Figure S2. The impact of ZNF397-deficiency on AR protein and AR cistrome. Figure S3. ZNF397 is required for the activation of canonical AR transcriptional program. Figure S4. ZNF397-KO impairs DHT-induced AR signaling activation. Figure S5. ZNF397-KO promotes multilineage and lineage plastic gene expression. Figure S6. ZNF397-KO promotes stem-like and EMT-like transcriptional programs. Figure S7. ZNF397-KO led to induction of TET2 downstream genes. Figure S8. ZNF397-KO promotes transcriptional activation of TET2 downstream genes. Figure S9. ZNF397-deficiency has bifurcated effects on AR-dependent vs AR-independent PCas. Figure S10. Targeting TET2-driven epigenetic rewiring to overcome resistance.
Year:
2024
Collaborators (14)
housheng hansen he
Senior Scientist
-
Zhao Wang
Associate Professor (Tenured)
Baylor College of Medicine
Ariella Hanker
Associate Professor
University of Texas Southwestern Medical Center
Ping Mu
Associate Professor
Yale University
Xiaoling Li
ARS
Yale University
Su Deng
Assistant Professor
Yale University
Hong Zhu
-
Guanghui Zhu
Assoicate professor
Sichuan University
Felix Y. Feng
University of California
Han Liang
The University of Texas MD Anderson Cancer Center
Carlos L. Arteaga
University of Texas Southwestern Medical Center
Yitao Tang
The University of Texas MD Anderson Cancer Center
Tao Wang
The University of Texas MD Anderson Cancer Center
Yunguan Wang
Assistant Professor
Cincinnati Children's Hospital Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.